Novavax, Inc. Stock price

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2023-12-07 pm EST Intraday chart for Novavax, Inc. 5-day change 1st Jan Change
5.525 USD -0.99% +0.45% -46.25%
Sales 2023 * 1.01B Sales 2024 * 1.05B Capitalization 657M
Net income 2023 * -402M Net income 2024 * -85M EV / Sales 2023 *
-0,07x
Net cash position 2023 * 733M Net cash position 2024 * 422M EV / Sales 2024 *
0,22x
P/E ratio 2023 *
-1,35x
P/E ratio 2024 *
-6,85x
Employees 1,992
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.90%
1 week+0.55%
Current month+0.55%
1 month-22.00%
3 months-39.56%
6 months-27.90%
Current year-46.21%
More quotes
1 week
5.42
Extreme 5.42
6.05
1 month
5.30
Extreme 5.3
7.49
Current year
5.30
Extreme 5.3
13.70
1 year
5.30
Extreme 5.3
18.55
3 years
5.30
Extreme 5.3
331.68
5 years
3.54
Extreme 3.54
331.68
10 years
3.54
Extreme 3.54
331.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 Jan. 22
President 63 2014
Director of Finance/CFO 57 2021
Members of the board TitleAgeSince
Director/Board Member 56 2022
Director/Board Member 57 2020
Director/Board Member 57 2020
More insiders
Date Price Change Volume
23-12-07 5.53 -0.90% 5,705,634
23-12-06 5.58 -0.18% 5,970,708
23-12-05 5.59 -2.78% 8,146,744
23-12-04 5.75 +3.23% 6,231,702
23-12-01 5.57 +1.27% 6,867,930

Delayed Quote Nasdaq, December 07, 2023 at 03:59 pm EST

More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.53USD
Average target price
19.6USD
Spread / Average Target
+254.43%
Consensus
  1. Stock
  2. Equities
  3. Stock Novavax, Inc. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer